Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Papp, Z; Édes, I; Fruhwald, S; De Hert, SG; Salmenperä, M; Leppikangas, H; Mebazaa, A; Landoni, G; Grossini, E; Caimmi, P; Morelli, A; Guarracino, F; Schwinger, RH; Meyer, S; Algotsson, L; Wikström, BG; Jörgensen, K; Filippatos, G; Parissis, JT; González, MJ; Parkhomenko, A; Yilmaz, MB; Kivikko, M; Pollesello, P; Follath, F.
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan.
Int J Cardiol. 2012; 159(2):82-87
Doi: 10.1016/j.ijcard.2011.07.022
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Fruhwald Sonja
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
- Find related publications in this database (using NLM MeSH Indexing)
-
Animals -
-
Cardiotonic Agents - pharmacology
-
Cardiovascular Diseases - drug therapy
-
Clinical Trials as Topic - methods
-
Consensus -
-
Humans -
-
Hydrazones - pharmacology
-
Pyridazines - pharmacology
-
Vasodilator Agents - pharmacology
- Find related publications in this database (Keywords)
-
Levosimendan
-
Mechanism of action
-
Ca2+-sensitization
-
Positive inotropy
-
Vasodilation
-
Cardioprotection